Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
<h4>Purpose</h4>To analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD).<h4>Methods</h4>This study included 93 eyes of 90 patients. The incidence of em...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0259879 |
| _version_ | 1798034321927307264 |
|---|---|
| author | Ryo Mukai Hidetaka Matsumoto Hideo Akiyama |
| author_facet | Ryo Mukai Hidetaka Matsumoto Hideo Akiyama |
| author_sort | Ryo Mukai |
| collection | DOAJ |
| description | <h4>Purpose</h4>To analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD).<h4>Methods</h4>This study included 93 eyes of 90 patients. The incidence of emerging IOI was analyzed. The patients were classified into IOI or non-IOI groups, and background clinical characteristics in each group were compared.<h4>Results</h4>IOI occurred in 14 eyes of 14 cases (16%; five women, nine men [5:9]; IOI group) after IVBr; contrastingly, no IOI occurred in 76 patients (10 women, 66 men [10:66]; non-IOI group). The mean ages in IOI and non-IOI groups were 79.4 ± 8.1 and 73.8 ± 8.9 years old, respectively, and the average age in the IOI group was significantly higher than that in the non-IOI group (P = 0.0425). In addition, the percentages of females in the IOI and non-IOI groups were 43% and 13%, respectively, and IOI occurred predominantly in females (odds ratio: 4.95, P = 0.0076). Moreover, the prevalence of diabetes in the IOI and non-IOI groups was 64% and 32%, respectively, with a significant difference (odds ratio: 3.90, P = 0.0196). In contrast, the prevalence of hypertension in the IOI and non-IOI groups was 36% and 57%, respectively, with no significant difference (P = 0.15).<h4>Conclusion</h4>The comparison of clinical profiles of IOI or non-IOI cases in IVBr treatment for AMD suggests that the risk factors for IOI are old age, female sex, and history of diabetes; however, IOI with vasculitis or vascular occlusion in this cohort does not seem to cause severe visual impairment. Further studies are required to investigate potential risk factors for IOI. |
| first_indexed | 2024-04-11T20:42:35Z |
| format | Article |
| id | doaj.art-77bafc2f1aca45baaa4a34ea812278d9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T20:42:35Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-77bafc2f1aca45baaa4a34ea812278d92022-12-22T04:04:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011612e025987910.1371/journal.pone.0259879Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.Ryo MukaiHidetaka MatsumotoHideo Akiyama<h4>Purpose</h4>To analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD).<h4>Methods</h4>This study included 93 eyes of 90 patients. The incidence of emerging IOI was analyzed. The patients were classified into IOI or non-IOI groups, and background clinical characteristics in each group were compared.<h4>Results</h4>IOI occurred in 14 eyes of 14 cases (16%; five women, nine men [5:9]; IOI group) after IVBr; contrastingly, no IOI occurred in 76 patients (10 women, 66 men [10:66]; non-IOI group). The mean ages in IOI and non-IOI groups were 79.4 ± 8.1 and 73.8 ± 8.9 years old, respectively, and the average age in the IOI group was significantly higher than that in the non-IOI group (P = 0.0425). In addition, the percentages of females in the IOI and non-IOI groups were 43% and 13%, respectively, and IOI occurred predominantly in females (odds ratio: 4.95, P = 0.0076). Moreover, the prevalence of diabetes in the IOI and non-IOI groups was 64% and 32%, respectively, with a significant difference (odds ratio: 3.90, P = 0.0196). In contrast, the prevalence of hypertension in the IOI and non-IOI groups was 36% and 57%, respectively, with no significant difference (P = 0.15).<h4>Conclusion</h4>The comparison of clinical profiles of IOI or non-IOI cases in IVBr treatment for AMD suggests that the risk factors for IOI are old age, female sex, and history of diabetes; however, IOI with vasculitis or vascular occlusion in this cohort does not seem to cause severe visual impairment. Further studies are required to investigate potential risk factors for IOI.https://doi.org/10.1371/journal.pone.0259879 |
| spellingShingle | Ryo Mukai Hidetaka Matsumoto Hideo Akiyama Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS ONE |
| title | Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. |
| title_full | Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. |
| title_fullStr | Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. |
| title_full_unstemmed | Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. |
| title_short | Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. |
| title_sort | risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age related macular degeneration |
| url | https://doi.org/10.1371/journal.pone.0259879 |
| work_keys_str_mv | AT ryomukai riskfactorsforemergingintraocularinflammationafterintravitrealbrolucizumabinjectionforagerelatedmaculardegeneration AT hidetakamatsumoto riskfactorsforemergingintraocularinflammationafterintravitrealbrolucizumabinjectionforagerelatedmaculardegeneration AT hideoakiyama riskfactorsforemergingintraocularinflammationafterintravitrealbrolucizumabinjectionforagerelatedmaculardegeneration |